Drugs that contain Dabigatran Etexilate Mesylate

1. List of Pradaxa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7932273 BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
Sep, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6087380

(Pediatric)

BOEHRINGER INGELHEIM Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
Jun, 2022

(7 months ago)

US9925174 BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
Jun, 2023

(4 months from now)

US9925174

(Pediatric)

BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
Dec, 2023

(10 months from now)

US7932273

(Pediatric)

BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
Mar, 2026

(3 years from now)

US7866474 BOEHRINGER INGELHEIM Film container
Aug, 2027

(4 years from now)

US7866474

(Pediatric)

BOEHRINGER INGELHEIM Film container
Mar, 2028

(5 years from now)

US9034822 BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds
Jan, 2031

(7 years from now)

US9034822

(Pediatric)

BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds
Jul, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Jun 21, 2024
Pediatric Exclusivity (PED) Dec 21, 2024

Market Authorisation Date: 19 October, 2010

Treatment: Method of reversing the anticoagulant effect of dabigatran using idarucizumab

Dosage: CAPSULE;ORAL

How can I launch a generic of PRADAXA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic